Since 1946, the National Chamber for the Pharmaceutical Industry (CANIFARMA) has been working to represent and further the interests of the Mexican pharmaceutical sector in relation to governmental authorities. In this article, Rafael Gual, General Director of CANIFARMA, speaks about the chamber’s objectives regarding sanitary regulation, research and innovation, and economic development.
In the last three years CANIFARMA has been working tirelessly in defining a development program for the pharmaceutical sector, which is unprecedented in terms of depth and scope.
In brief, the development program involves transforming the pharmaceutical sector into one of the most important economic engines for Mexico, and a new route of economic development for the country.
All essential aspects of the country’s health are touched by the pharmaceutical sector, since we help to improve life expectancy and the quality of life of the population; we generate knowledge through the intrinsic relationship of our business with research, innovation and applied science; and we also impact the economy, since we create high quality jobs that foster a virtuous circle of human capital, productivity, welfare and development.
All essential aspects of the country’s health are touched by the pharmaceutical sector”
In recent years there have been significant advances in regulatory matters in which the concurrence, understanding and cooperation between authorities and industry have made a notable difference, all working in favor of Mexico.
As for research, Mexico has a great potential yet to be properly exploited. The infrastructure and human resources available in our country allows us to predict that under favorable conditions, we can become the most important clinical research development center for Latin America, which will bring significant technological and economic spillover for our country.
Besides, our sector is currently the second largest productive sub-branch for the country, as it shares more than seven percent of gross domestic product for the manufacturing sector, and generates almost four hundred thousand jobs, both direct and indirect. We maintain our growth dynamics in both the domestic and external markets, with a significant increase in exports, even in times of crisis.
Our sector has always been recognized because of its cohesion and unity, and exerted a positive influence and important representation in the economic and political scene of our country.”
To support all these facts, CANIFARMA recently completed the first census of the pharmaceutical industry, which confirms and validates most of the data we already knew, and also gives us a strong base that allows us to foresee a promising future in terms of investment in new manufacturing facilities, clinical research, employment generation and financial development.
With all the input and ideas provided by industry experts, we have finalized the Development Program for the Pharmaceutical Sector, which contemplates three progressive stages of development along the first hundred days of the new government in office, the first four years, and the last two years for project consolidation. These three stages are referred to three aspects; namely, the improvement of the regulatory framework, innovation and research, and industrial policy.
Our sector has always been recognized because of its cohesion and unity, and exerted a positive influence and important representation in the economic and political scene of our country. We have met innumerable challenges with integrity and consistency. The challenge now is to persevere in this spirit for the growth and benefit of our industry and our country.
To read more articles and interviews on Mexico, and to download PharmaBoardroom’s latest free report on the country, click here.
CANIFARMA
Cuauhtémoc 1481,
Santa Cruz Atoyac,
03310 Benito Juárez,
Distrito Federal, Mexico
+52 55 5688 9477
+52 55 5688 9477
